{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:44:16Z","timestamp":1782139456368,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2025.116195","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:57:29Z","timestamp":1766159849000},"page":"116195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment \u2013 Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3837-1640","authenticated-orcid":false,"given":"Noah","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8096-7402","authenticated-orcid":false,"given":"Tim","family":"Zell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7343-7256","authenticated-orcid":false,"given":"Ali Zeinal","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara L.","family":"Blomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Belz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2794-0003","authenticated-orcid":false,"given":"Benjamin","family":"Deitert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Geidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"R\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-9511","authenticated-orcid":false,"given":"Daniel J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"von Wasielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-7407","authenticated-orcid":false,"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-9486","authenticated-orcid":false,"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-114X","authenticated-orcid":false,"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1312","authenticated-orcid":false,"given":"Fabian","family":"Ziller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116195_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat Rev Dis Prim"},{"issue":"7","key":"10.1016\/j.ejca.2025.116195_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.116195_bib5","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.116195_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ejca.2025.116195_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.116195_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116195_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102322","article-title":"Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities","volume":"102","author":"Bauer","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.ejca.2025.116195_bib10","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood.2020005710","article-title":"Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model","volume":"137","author":"Feinauer","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ejca.2025.116195_bib11","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","article-title":"von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans","volume":"125","author":"Bauer","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2025.116195_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006456","article-title":"Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors","volume":"11","author":"Stadler","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3324\/haematol.2022.281315","article-title":"Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality","volume":"108","author":"Karampinis","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejca.2025.116195_bib14","first-page":"1210","article-title":"Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor","volume":"86","author":"Bromberg","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejca.2025.116195_bib15","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(07)70125-1","article-title":"Tissue factor and PAR signaling in tumor progression","volume":"120","author":"Ruf","year":"2007","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib16","article-title":"Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain","volume":"3","author":"Robador","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.ejca.2025.116195_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-021-02458-8","article-title":"Roles of factor Xa beyond coagulation","volume":"52","author":"Ruf","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"39","key":"10.1016\/j.ejca.2025.116195_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell\u2013synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejca.2025.116195_bib19","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","author":"Yang","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2025.116195_bib20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00262-005-0669-2","article-title":"Cyclooxygenase inhibitors modulate NK activities that control metastatic disease","volume":"54","author":"Kundu","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2025.116195_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00259","article-title":"Differential cytotoxicity but augmented IFN-\u00ce3 secretion by NK cells after interaction with monocytes from humans, and those from wild type and myeloid-specific COX-2 knockout mice","volume":"6","author":"Tseng","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.116195_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2025.116195_bib23","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ejca.2025.116195_bib24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116195_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.116195_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-21-0244","article-title":"Effect of aspirin on melanoma incidence in older persons: extended follow-up of a large randomized double-blind placebo-controlled trial","volume":"15","author":"Yan","year":"2022","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12967-021-02712-w","article-title":"Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients","volume":"19","author":"Johannet","year":"2021","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116195_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2025.116195_bib29","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.3390\/cancers13205103","article-title":"Anticoagulation with factor Xa inhibitors is associated with improved overall response and progression-free survival in patients with metastatic malignant melanoma receiving immune checkpoint inhibitors-A retrospective, real-world cohort study","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2025.116195_bib30","article-title":"Aspirin use and common cancer risk: a meta-analysis of cohort studies and randomized controlled trials","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"9826","key":"10.1016\/j.ejca.2025.116195_bib31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116195_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115159","article-title":"Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy \u2013 A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg","volume":"214","author":"K\u00f6tt","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.116195_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"42","key":"10.1016\/j.ejca.2025.116195_bib34","doi-asserted-by":"crossref","first-page":"68527","DOI":"10.18632\/oncotarget.11832","article-title":"Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis","volume":"7","author":"Goertz","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ejca.2025.116195_bib35","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"Klerk","year":"2005","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.ejca.2025.116195_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/cncr.22892","article-title":"A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications","volume":"110","author":"Kuderer","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.116195_bib37","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ejca.2025.116195_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jso.20728","article-title":"Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer","volume":"95","author":"Icli","year":"2007","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.116195_bib39","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.ejca.2025.116195_bib40","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E","article-title":"Subcutaneous heparin treatment increases survival in small cell lung cancer. \u201cPetites Cellules\u201d Group","volume":"74","author":"Lebeau","year":"1994","journal-title":"Cancer"},{"issue":"38","key":"10.1016\/j.ejca.2025.116195_bib42","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.2174\/1381612825666190925163827","article-title":"A brief review of cardiovascular diseases, associated risk factors and current treatment regimes","volume":"25","author":"Flora","year":"2019","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.ejca.2025.116195_bib43","first-page":"1","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Prim"},{"issue":"8","key":"10.1016\/j.ejca.2025.116195_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.ejca.2025.116195_bib45","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","article-title":"Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer","volume":"42","author":"Cal\u00ec","year":"2024","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.ejca.2025.116195_bib46","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejca.2025.116195_bib47","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:46:07Z","timestamp":1781685967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"alternative-id":["S0959804925010810"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116195","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment \u2013 Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116195"}}